TCRX FY 2022 Earnings — TScan Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TCRXTScan Therapeutics, Inc.

$69M

FY 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$14M+33.5% YoY

Gross Profit

$14M100.0% margin

Operating Income

-$67M-492.3% margin

Net Income

-$66M-489.3% margin

EPS (Diluted)

$-2.74

Cash Flow

Operating Cash Flow

-$67M

Free Cash Flow

-$71M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$199M

Total Liabilities

$100M

Stockholders' Equity

$99M

Cash & Equivalents

$120M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$14M	$10M	+33.5%
Gross Profit	$14M	$10M	+33.5%
Operating Income	-$67M	-$49M	-37.0%
Net Income	-$66M	-$49M	-36.2%